In recent years, the MENA region has taken a center stage in the pharmaceutical industry, mainly due to huge investment in both the private and public sectors, the introduction of mass health insurance and several moves to liberalize national economies. Egypt, Saudi Arabia, Algeria, South Africa, Jordan, UAE, Lebanon and Kuwait are some of the major markets in our territories.
MENA will remain one of the fastest growing regions in the world over the next few years due to:
In the recent years MENA market has a rapid growth in healthcare sector. It is a fastest growing market in the world. MENA is economically diverse region, which is rich in oil export. The expenditure of MENA countries for health care sector has been raised more than US and UK.
The region includes a mix of some relatively wealthy but not-yet-saturated markets, fast-growing emerging markets, and undeveloped markets resulting in the long term growth prospects. MENA Markets mostly depend on import as there is lack in research and development. As they do not have large scale manufacturing units and effect of western countries brands opposes local manufactured products also. These creates an opportunity for Western companies to get facilitated in MENA Market.
MSP helps companies seize the opportunity of entering the fastest-growing markets of the MENA region, while managing the risk.
Southeast Asia is a growing pharmaceutical market. Much like Latin America, the countries of southeast Asia, especially the members of the Association of Southeast Asian Nations (ASIAN: The current territories of India, Pakistan, Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Sri Lanka, Brunei, Burma, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam), have taken initial steps towards seeking more harmonized regulation of pharmaceutical and medical-device industries.